The role of m6A methylation in therapy resistance in cancer
Cancer therapy resistance is the main cause of cancer treatment failure. The mechanism of therapy resistance is a hot topic in epigenetics. As one of the most common RNA modifications, N6-methyladenosine (m6A)... (Source: Molecular Cancer)
Source: Molecular Cancer - June 1, 2023 Category: Cancer & Oncology Authors: Hengzhao Zhuang, Bo Yu, Dan Tao, Xiaoyan Xu, Yijun Xu, Jian Wang, Yang Jiao and Lili Wang Tags: Review Source Type: research
EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin?
Epithelial mesenchymal transition (EMT) and mesenchymal epithelial transition (MET) are genetic determinants of cellular plasticity. These programs operate in physiological (embryonic development, wound healin... (Source: Molecular Cancer)
Source: Molecular Cancer - May 31, 2023 Category: Cancer & Oncology Authors: Azamat Akhmetkaliyev, Noura Alibrahim, Darya Shafiee and Eugene Tulchinsky Tags: Review Source Type: research
A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer
In this study, the impact of the IGF2BP family of RNA-binding proteins on CRC chemoresistance was investigated using in... (Source: Molecular Cancer)
Source: Molecular Cancer - May 30, 2023 Category: Cancer & Oncology Authors: Sandra Kendzia, Susanne Franke, Tarek Kr öhler, Nicole Golob-Schwarzl, Caroline Schweiger, Anna M. Toeglhofer, Christina Skofler, Stefan Uranitsch, Amin El-Heliebi, Julia Fuchs, Andreas Punschart, Philipp Stiegler, Marlen Keil, Jens Hoffmann, David Hende Tags: Research Source Type: research
IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression
Neuroblastoma is the most common solid tumor in infants accounting for approximately 15% of all cancer-related deaths. Over 50% of high-risk neuroblastoma relapse, emphasizing the need of novel drug targets an... (Source: Molecular Cancer)
Source: Molecular Cancer - May 29, 2023 Category: Cancer & Oncology Authors: Sven Hagemann, Danny Misiak, Jessica L. Bell, Tommy Fuchs, Marcell I. Lederer, Nadine Bley, Monika H ämmerle, Ehab Ghazy, Wolfgang Sippl, Johannes H. Schulte and Stefan Hüttelmaier Tags: Research Source Type: research
New opportunities for RGD-engineered metal nanoparticles in cancer
The advent of nanotechnology has opened new possibilities for bioimaging. Metal nanoparticles (such as gold, silver, iron, copper, etc.) hold tremendous potential and offer enormous opportunities for imaging a... (Source: Molecular Cancer)
Source: Molecular Cancer - May 25, 2023 Category: Cancer & Oncology Authors: Wei Qin, Jyoti Chandra, Mohammed A.S. Abourehab, Neelima Gupta, Zhe-Sheng Chen, Prashant Kesharwani and Hui-Ling Cao Tags: Review Source Type: research
EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer
Enhancer of zeste homolog 2 (EZH2), the key catalytic subunit of polycomb repressive complex 2 (PRC2), is overexpressed and plays an oncogenic role in various cancers through catalysis-dependent or catalysis-i... (Source: Molecular Cancer)
Source: Molecular Cancer - May 20, 2023 Category: Cancer & Oncology Authors: Jianfeng Chen, Jing Han Hong, Yulin Huang, Shini Liu, Jiaxin Yin, Peng Deng, Yichen Sun, Zhaoliang Yu, Xian Zeng, Rong Xiao, Jason Yongsheng Chan, Peiyong Guan, Yali Wang, Peili Wang, Lizhen Liu, Shijun Wen & hellip; Tags: Research Source Type: research
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
The discovery of functionally relevant KRAS effectors in lung and pancreatic ductal adenocarcinoma (LUAD and PDAC) may yield novel molecular targets or mechanisms amenable to inhibition strategies. Phospholipi... (Source: Molecular Cancer)
Source: Molecular Cancer - May 20, 2023 Category: Cancer & Oncology Authors: Rodrigo Entrialgo-Cadierno, Cristina Cueto-Ure ña, Connor Welch, Iker Feliu, Irati Macaya, Laura Vera, Xabier Morales, Sandra Vietti Michelina, Pietro Scaparone, Ines Lopez, Elodie Darbo, Oihane Erice, Adrian Vallejo, Haritz Moreno, Ainhoa Goñi-Salaverr Tags: Research Source Type: research
Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy
Checkpoint blockade immunotherapy, represented by PD-1 or PD-L1 antibody treatment, has been of tremendous success in clinical practice. However, the low clinical response rate and lack of biomarkers for predi... (Source: Molecular Cancer)
Source: Molecular Cancer - May 16, 2023 Category: Cancer & Oncology Authors: Zongzhi Liu, Xiang Li, Yibo Gao, Jiejie Liu, Yating Feng, Yang Liu, Junyun Wang, Chunmeng Wang, Dongrui Wang, Jie He, Weidong Han, Qian Mei and Yingli Sun Tags: Research Source Type: research
CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks
CAR T cell-based therapies have revolutionized the treatment of hematological malignancies such as leukemia and lymphoma within the last years. In contrast to the success in hematological cancers, the treatmen... (Source: Molecular Cancer)
Source: Molecular Cancer - May 12, 2023 Category: Cancer & Oncology Authors: Lusine Hovhannisyan, Carsten Riether, Daniel M. Aebersold, Michaela Medov á and Yitzhak Zimmer Tags: Review Source Type: research
Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer
RNA modifications are important regulators of transcript activity and an increasingly emerging body of data suggests that the epitranscriptome and its associated enzymes are altered in human tumors. (Source: Molecular Cancer)
Source: Molecular Cancer - May 12, 2023 Category: Cancer & Oncology Authors: Vanessa Ortiz-Barahona, Marta Soler, Veronica Davalos, Carlos A. Garc ía-Prieto, Maxime Janin, Fernando Setien, Irene Fernández-Rebollo, Joan J. Bech-Serra, Carolina De La Torre, Sonia Guil, Alberto Villanueva, Pei-Hong Zhang, Li Yang, Marco Guarnacci, Tags: Research Source Type: research
Aberrant m5C hypermethylation mediates intrinsic resistance to gefitinib through NSUN2/YBX1/QSOX1 axis in EGFR-mutant non-small-cell lung cancer
RNA 5-methylcytosine (m5C) modification plays critical roles in the pathogenesis of various tumors. However, the function and molecular mechanism of RNA m5C modification in tumor drug resistance remain unclear. (Source: Molecular Cancer)
Source: Molecular Cancer - May 9, 2023 Category: Cancer & Oncology Authors: Yueqin Wang, Jingyao Wei, Luyao Feng, Ouwen Li, Lan Huang, Shaoxuan Zhou, Yingjie Xu, Ke An, Yu Zhang, Ruiying Chen, Lulu He, Qiming Wang, Han Wang, Yue Du, Ruijuan Liu, Chunmin Huang & hellip; Tags: Research Source Type: research
Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
Chimeric antigen receptor (CAR) T-cell therapy has made remarkable progress in cancer immunotherapy, but several challenges with unclear mechanisms hinder its wide clinical application. Single-cell sequencing ... (Source: Molecular Cancer)
Source: Molecular Cancer - May 6, 2023 Category: Cancer & Oncology Authors: Shengkang Huang, Xinyu Wang, Yu Wang, Yajing Wang, Chenglong Fang, Yazhuo Wang, Sifei Chen, Runkai Chen, Tao Lei, Yuchen Zhang, Xinjie Xu and Yuhua Li Tags: Review Source Type: research
Circulating biosignatures in multiple myeloma and their role in multidrug resistance
A major obstacle to chemotherapeutic success in cancer treatment is the development of drug resistance. This occurs when a tumour fails to reduce in size after treatment or when there is clinical relapse after... (Source: Molecular Cancer)
Source: Molecular Cancer - April 29, 2023 Category: Cancer & Oncology Authors: S. Rajeev Krishnan and M. Bebawy Tags: Review Source Type: research
Retraction Note: Systematic analyses reveal long non-coding RNA (PTAF)-mediated promotion of EMT and invasion-metastasis in serous ovarian cancer
This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s12943-018-0844-7. (Source: Molecular Cancer)
Source: Molecular Cancer - April 28, 2023 Category: Cancer & Oncology Authors: Haihai Liang, Xiaoguang Zhao, Chengyu Wang, Jian Sun, Yingzhun Chen, Guoyuan Wang, Lei Fang, Rui Yang, Mengxue Yu, Yunyan Gu and Hongli Shan Tags: Retraction Note Source Type: research
CircZBTB44 promotes renal carcinoma progression by stabilizing HK3 mRNA structure
CircZBTB44 (hsa_circ_0002484) has been identified to be upregulated in renal cell carcinoma (RCC) tissues, while its role and contribution in RCC remain elusive. We confirmed the overexpression of circZBTB44 i... (Source: Molecular Cancer)
Source: Molecular Cancer - April 27, 2023 Category: Cancer & Oncology Authors: Tushuai Li, Yue Gu, Baocai Xu, Kamil Kuca, Jie Zhang and Wenda Wu Tags: Research Source Type: research
